Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Summit Therapeutics expands enrolment in Phase 2 PhaseOut DMD trial

Summit is extending an invitation to DMD sufferers who participated in the Phase 1 trial of ezutromid but who were not initially eligible for the Phase II trial to get back in the programme
Small boy crying on the stairs
Patients are eligible to participate regardless of their ambulatory status or age.

Summit Therapeutics PLC (NASDAQ:SMMT, LON:SUMM) has opened enrolment in a planned additional group in its Phase 2 open-label clinical trial called PhaseOut DMD.

PhaseOut DMD is a trial of ezutromid, Summit's drug candidate for the treatment of Duchenne Muscular Dystrophy, a rare muscle-wasting disease that affects boys and young men.

READ: Summit Therapeutics shares jump as initial results of clinical trial for Duchenne muscular dystrophy treatment shows "further positive findings"

Enrolment is open to patients who participated in Phase 1 clinical trials of ezutromid but who did not meet the entry criteria for the main PhaseOut DMD cohorts.

Study assessments will include functional tests appropriate for the patient's ambulatory status, cardiac magnetic resonance imaging (MRI) and lung function tests.

"We are extremely grateful to the patients who participated in our Phase 1 clinical trials and contributed to ezutromid's clinical advancement, but were not initially eligible to participate in our Phase 2 clinical trial. Accordingly, we are pleased to open this additional group in our Phase 2 and provide these patients with the opportunity to receive ezutromid treatment," said Dr David Roblin, the chief operating officer and medical officer of Summit. 

"We expect the data collected from this additional group of patients will help expand our understanding of ezutromid's safety and efficacy profile across a broader patient population," he added.

Shares in Summit were up a penny at 181p in lunchtime trading.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

July 11 2018
Valirx raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.
nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use